The automotive industry has reduced crash testing costs by 85% using computer executed Finite Element Analysis [FEA] while complying  fully with National Highway Traffic Safety Administration [NHTSA] mandated vehicle safety requirements.

CB-TSS technology offers a similar [FEA] approach  to model physiological behavior, allowing pharmaceutical manufacturers to simulate, for example, patient response to drugs during clinical trials.

.The prospect of a significant reduction in the cost of the clinical phases is attractive, since these trials constitute the  major component of the new drug R&D budget.  However, it is interesting to note that automotive managers are more impressed with the depth of design insight provided by simulation studies, and the opportunity to telescope the development timeline, than in the savings that accrue from not smashing thousands of $20,000 cars into brick walls each year.

It is also of interest to note that the compute cycles GM uses to model vehicle crashes today constitute 65% of the total compute cycles used by the entire company [accounting, sales & marketing, manufacturing, other engineering, and so fourth.].  And this fraction is expected to increase rapidly in the next decade as the industry moves to High Performance Computing [HPC] machines, including petaflop [10¹⁵ floating point ops/sec] supercomputers which are a million times  faster than today's desktops.